BACKGROUND: Therapeutic hypothermia is recommended for comatose adults after witnessed out-of-hospital cardiac arrest, but data about this intervention in children are limited. METHODS: We conducted this trial of two targeted temperature interventions at 38 children's hospitals involving children who remained unconscious after out-of-hospital cardiac arrest. Within 6 hours after the return of circulation, comatose patients who were older than 2 days and younger than 18 years of age were randomly assigned to therapeutic hypothermia (target temperature, 33.0°C) or therapeutic normothermia (target temperature, 36.8°C). The primary efficacy outcome, survival at 12 months after cardiac arrest with a Vineland Adaptive Behavior Scales, second edition (VABS-II), score of 70 or higher (on a scale from 20 to 160, with higher scores indicating better function), was evaluated among patients with a VABS-II score of at least 70 before cardiac arrest. RESULTS: A total of 295 patients underwent randomization. Among the 260 patients with data that could be evaluated and who had a VABS-II score of at least 70 before cardiac arrest, there was no significant difference in the primary outcome between the hypothermia group and the normothermia group (20% vs. 12%; relative likelihood, 1.54; 95% confidence interval [CI], 0.86 to 2.76; P=0.14). Among all the patients with data that could be evaluated, the change in the VABS-II score from baseline to 12 months was not significantly different (P=0.13) and 1-year survival was similar (38% in the hypothermia group vs. 29% in the normothermia group; relative likelihood, 1.29; 95% CI, 0.93 to 1.79; P=0.13). The groups had similar incidences of infection and serious arrhythmias, as well as similar use of blood products and 28-day mortality. CONCLUSIONS: In comatose children who survived out-of-hospital cardiac arrest, therapeutic hypothermia, as compared with therapeutic normothermia, did not confer a significant benefit in survival with a good functional outcome at 1 year. (Funded by the National Heart, Lung, and Blood Institute and others; THAPCA-OH ClinicalTrials.gov number, NCT00878644.).
BACKGROUND: Therapeutic hypothermia is recommended for comatose adults after witnessed out-of-hospital cardiac arrest, but data about this intervention in children are limited. METHODS: We conducted this trial of two targeted temperature interventions at 38 children's hospitals involving children who remained unconscious after out-of-hospital cardiac arrest. Within 6 hours after the return of circulation, comatose patients who were older than 2 days and younger than 18 years of age were randomly assigned to therapeutic hypothermia (target temperature, 33.0°C) or therapeutic normothermia (target temperature, 36.8°C). The primary efficacy outcome, survival at 12 months after cardiac arrest with a Vineland Adaptive Behavior Scales, second edition (VABS-II), score of 70 or higher (on a scale from 20 to 160, with higher scores indicating better function), was evaluated among patients with a VABS-II score of at least 70 before cardiac arrest. RESULTS: A total of 295 patients underwent randomization. Among the 260 patients with data that could be evaluated and who had a VABS-II score of at least 70 before cardiac arrest, there was no significant difference in the primary outcome between the hypothermia group and the normothermia group (20% vs. 12%; relative likelihood, 1.54; 95% confidence interval [CI], 0.86 to 2.76; P=0.14). Among all the patients with data that could be evaluated, the change in the VABS-II score from baseline to 12 months was not significantly different (P=0.13) and 1-year survival was similar (38% in the hypothermia group vs. 29% in the normothermia group; relative likelihood, 1.29; 95% CI, 0.93 to 1.79; P=0.13). The groups had similar incidences of infection and serious arrhythmias, as well as similar use of blood products and 28-day mortality. CONCLUSIONS: In comatose children who survived out-of-hospital cardiac arrest, therapeutic hypothermia, as compared with therapeutic normothermia, did not confer a significant benefit in survival with a good functional outcome at 1 year. (Funded by the National Heart, Lung, and Blood Institute and others; THAPCA-OH ClinicalTrials.gov number, NCT00878644.).
Authors: Mary Ann Peberdy; Clifton W Callaway; Robert W Neumar; Romergryko G Geocadin; Janice L Zimmerman; Michael Donnino; Andrea Gabrielli; Scott M Silvers; Arno L Zaritsky; Raina Merchant; Terry L Vanden Hoek; Steven L Kronick Journal: Circulation Date: 2010-11-02 Impact factor: 29.690
Authors: J Hutchison; R Ward; J Lacroix; P Hébert; P Skippen; M Barnes; P Meyer; K Morris; H Kirpalani; R Singh; P Dirks; D Bohn; D Moher Journal: Dev Neurosci Date: 2006 Impact factor: 2.984
Authors: Aaron J Donoghue; Vinay Nadkarni; Robert A Berg; Martin H Osmond; George Wells; Lisa Nesbitt; Ian G Stiell Journal: Ann Emerg Med Date: 2005-08-08 Impact factor: 5.721
Authors: Seetha Shankaran; Abbot R Laptook; Richard A Ehrenkranz; Jon E Tyson; Scott A McDonald; Edward F Donovan; Avroy A Fanaroff; W Kenneth Poole; Linda L Wright; Rosemary D Higgins; Neil N Finer; Waldemar A Carlo; Shahnaz Duara; William Oh; C Michael Cotten; David K Stevenson; Barbara J Stoll; James A Lemons; Ronnie Guillet; Alan H Jobe Journal: N Engl J Med Date: 2005-10-13 Impact factor: 91.245
Authors: Ericka L Fink; Robert S B Clark; Patrick M Kochanek; Michael J Bell; R Scott Watson Journal: Pediatr Crit Care Med Date: 2010-01 Impact factor: 3.624
Authors: Abbot Laptook; Jon Tyson; Seetha Shankaran; Scott McDonald; Richard Ehrenkranz; Avroy Fanaroff; Edward Donovan; Ronald Goldberg; T Michael O'Shea; Rosemary D Higgins; W Kenneth Poole Journal: Pediatrics Date: 2008-09 Impact factor: 7.124
Authors: James S Hutchison; Roxanne E Ward; Jacques Lacroix; Paul C Hébert; Marcia A Barnes; Desmond J Bohn; Peter B Dirks; Steve Doucette; Dean Fergusson; Ronald Gottesman; Ari R Joffe; Haresh M Kirpalani; Philippe G Meyer; Kevin P Morris; David Moher; Ram N Singh; Peter W Skippen Journal: N Engl J Med Date: 2008-06-05 Impact factor: 91.245
Authors: James R Christensen; Beth S Slomine; Faye S Silverstein; Kent Page; Richard Holubkov; J Michael Dean; Frank W Moler Journal: Pediatr Crit Care Med Date: 2019-06 Impact factor: 3.624
Authors: Rebecca Ichord; Faye S Silverstein; Beth S Slomine; Russell Telford; James Christensen; Richard Holubkov; J Michael Dean; Frank W Moler Journal: Neurology Date: 2018-06-08 Impact factor: 9.910
Authors: Frank W Moler; Faye S Silverstein; Vinay M Nadkarni; Kathleen L Meert; Samir H Shah; Beth Slomine; James Christensen; Richard Holubkov; Kent Page; J Michael Dean Journal: Resuscitation Date: 2018-12-17 Impact factor: 5.262
Authors: Kacey B Anderson; Samuel M Poloyac; Patrick M Kochanek; Philip E Empey Journal: Ther Hypothermia Temp Manag Date: 2016-09-13 Impact factor: 1.286